Whole-body dose from tomotherapy delivery

Purpose: To measure whole-body dose in tomotherapy of the head and neck region resulting from internal patient scatter and linear accelerator leakage.Methods and Materials: Treatments are performed using a commercial computer-controlled intensity modulated radiation therapy planning and delivery system (Peacock, NOMOS Corp.) and a 6-MV linear accelerator (Clinac 6/100, Varian Corp.). The patient dose outside the treatment field is measured in a water-equivalent phantom using thermoluminescent dosimetry. The whole-body dose components from internal scatter and leakage are separately determined. The use of fixed-portal leakage and scattered radiation measurements to estimate the whole-body dose from tomotherapy is evaluated.Results: The internally scattered dose is significant near the target, but becomes negligible relative to the leakage dose beyond 15 cm from the target. Dose at 10 cm from the target volume, due to internal scatter and leakage, is approximately 2.5% of the total target dose, reducing to 0.5% at 30 cm. The measured dose is relatively uniform throughout the phantom.Conclusion: The whole-body dose equivalent from a tomotherapy treatment is greater than that from conventional radiation therapy. Further studies are required to assess the trade-off between improved dose distribution conformality and a possible slight increase in radiation-induced fatal malignancies. The accuracy of using fixed-portal leakage and scattered dose measurements to estimate the whole-body dose from tomotherapy treatments is adequate, if the appropriate fixed-portal field size equivalent is used.     

Suitability of superficial electron paramagnetic resonance dosimetry for in vivo measurement and verification of cumulative total doses during IMRT: A proof of principle

PurposeThe present study investigates superficial in vivo dosimetry (IVD) by means of a previously proposed electron paramagnetic resonance (EPR) dosimetry system aiming at measuring and verifying total doses delivered by complex radiotherapy treatments. In view of novel regulatory requirements in Germany, differences between measured and planned total doses to the EPR dosimeters are analyzed and compared to reporting thresholds for significant occurrences.MethodsEPR dosimeters, each consisting of one lithium formate monohydrate (LFM) and one polycrystalline l-alanine (ALA) pellet, were attached to the surface of an anthropomorphic head phantom. Three head and neck treatments with total target doses ranging from 30 to 64 Gy were fully delivered to the phantom by helical tomotherapy. During each treatment, eight EPR dosimeters were placed at distinct spots: (i) within or next to the planning target volume (PTV), (ii) near to organs at risk including the parotids and the lenses, (iii) at the thyroid lying out-of-field. EPR read out was always performed after all fractions were delivered. EPR results were compared to thermoluminescence dosimeter (TLD) measurements and to the planned total doses derived from the treatment planning system (TPS). Planned total doses to the EPR dosimeters ranged from about 2 to 64 Gy.ResultsBy taking uncertainties into account, the measured and planned doses were in good agreement. Exceptions occurred mainly at the thyroid (out-of-field) and lenses (extreme sparing). The maximum total dose difference between EPR results and corresponding planned doses was 1.3 Gy occurring at the lenses. Remarkably, each LFM and ALA pellet placed within or next to the PTV provided dose values that were within ±4% of the planned dose. Dose deviations from planned dose values were comparable for EPR and TLD measurements.ConclusionThe results of this proof of principle study suggests that superficial EPR-IVD is applicable in a wide dose range and in various irradiation conditions – being a valuable tool for monitoring cumulative total doses delivered by complex IMRT treatments. EPR-IVD in combination with helical tomotherapy is suitable to reliably detect local dose deviations at superficial dosimeter spots in the order of current national reporting thresholds for significant occurrences (i.e. 10%/4 Gy).     

Dose délivrée au patient lors de l’acquisition d’images par tomographie conique de haute énergie

PurposeTo study the dose delivered by a megavoltage cone beam computed tomography imaging system (MVCBCT) installed on a Oncor Impression^® linac (Siemens?).Materials and methodsThe acquisition of MVCBCT images was modelled in a treatment planning system by 67 photon beams (6 MV). A study was conducted to: compare the calculated and measured dose at the centre of a cylindrical phantom; compare the calculated and measured dose distributions in the Alderson-Rando phantom (pelvis); study the influence of MVCBCT image acquisition for the repositioning of a prostate cancer patient treated by 3D conformal radiotherapy (prescribed dose of 74 Gy), on the dose–volume histograms (DVH) for the treatment plus seven MVCBCT (protocol D1–3 and weekly), treatment plus 37 MVCBCT (one for each day of treatment).ResultsThe difference between calculated and measured doses at the centre of the cylindrical phantom was less than 3%. A deviation of 7% maximum was found between the dose distribution calculated in the Rando phantom and the measured doses normalized at the beam isocentre. The dose delivered at the isocentre was equal to 3,7 cGy for a “5 MU” protocol, with a maximum dose of 6 cGy. In the case of the patient considered, the acquisition of 37 MVCBCT corresponded to an additional mean dose to the PTV of 1.2 Gy for a protocol “5 MU” with a significant influence on the DVH.ConclusionIn view of this study, it appears that the doses delivered in frequent use of MVCBCT must be taken into account by the radiation oncologist in assessing the therapeutic dose delivered to the target volume and organs at risk.     

螺旋断层放疗MVCT成像剂量测量及其分析

背景与目的：螺旋断层放疗中治疗前／后通常采用MVCT（megavoltage coreputed tomography,MVCT）来实行图像引导下精确定位,成像过程中势必会增加患者的辐射剂量。通过体部及头部标准模体分别模拟患者MVCT成像条件来实现其剂量学测量及研究。方法：采用螺旋断层治疗机MVCT分别对圆柱形体部模体和自制标准头模体在不同螺距比（1．0、2．0、3．0）、扫描长度（4．8、7．2、9．6、12、14．4cm）及摆位条件下进行扫描,测量模体内各点扫描平均剂量变化,并对其剂量均匀性情况进行定性分析。结果：体部模体内MVCT扫描辐射剂量在0．599～2．876cGy之间：而头部模体点平均剂量为0．913～3．231cGy。测量结果表明,模体内所受照射剂量与螺距比值、扫描长度呈密切相关性;且MVCT扫描剂量与CT螺距值基本成反比关系。不同摆位条件下辐射剂量值沿模体径向大小而相应产生出其变化趋势。结论：实验结果有助于为治疗计划设计及图像引导治疗扫描范围提供较为现实而可靠的临床依据,减小患者治疗期间可能诱发肿瘤所获取的额外剂量。     

商用质子治疗计划系统射程计算精度的验证北大核心CSCD

目的测量并验证商用质子治疗计划系统RayStation V10的计算精度及质子射程的计算精度,为该系统的临床运用提供参考。方法在上海瑞金医院质子治疗装置上,使用仿真头部模体验证RayStation的计算精度,扫描获取模体的CT数据并导入计划系统,追加设置水箱使其紧贴于模体后,在水箱适当深度设置一个立方体靶区,设计处方剂量为200 cGy(相对生物效应)且束流垂直穿过模体的单野验证计划,实施照射后,比较测量结果和计划系统计算结果。结果使用RayStation默认设置制订验证计划时,测量得到的纵向剂量分布相比计算结果往深的方向移动约4 mm,表明RayStation过高估计了模体中组织等效材料的水等效厚度。为研究该误差来源,用实际束流测量模体中软组织等效材料的水等效厚度,根据测量结果,微调RayStation默认设置,发现纵向扩展布拉格峰测量结果和计算结果的误差可以缩小到2 mm。结论使用RayStation默认设置计算仿真模体的阻止本领,可能带来较大射程误差。使用组织分割和实测模体的组织水等效厚度相结合的方法,可改善治疗计划系统在仿真模体上的射程计算精度。此方法有望成为减小此类剂量算法误差的有效手段之一。     

Flattening filter free beams in SBRT and IMRT: dosimetric assessment of peripheral doses

Purpose

Recently, there has been a growing interest in operating medical linear accelerators without a flattening filter. Due to reduced scatter, leaf transmission and radiation head leakage a reduction of out-of-field dose is expected for flattening filter free beams. The aim of the present study was to determine the impact of unflattened beams on peripheral dose for advanced treatment techniques with a large number of MUs.

Material and methods

An Elekta Precise linac was modified to provide 6 and 10 MV photon beams without a flattening filter. Basic beam data were collected and implemented into the TPS Oncentra Masterplan (Nucletron). Leakage radiation, which predominantly contributes to peripheral dose at larger distances from the field edge, was measured using a Farmer type ionisation chamber. SBRT (lung) and IMRT (prostate, head&neck) treatment plans were generated for 6 and 10 MV for both flattened and unflattened beams. All treatment plans were delivered to the relevant anatomic region of an anthropomorphic phantom which was extended by a solid water slab phantom. Dosimetric measurements were performed with TLD-700 rods, radiochromic films and a Farmer type ionisation chamber. The detectors were placed within the slab phantom and positioned along the isocentric longitudinal axis.

Results

Using unflattened beams results in a reduction of treatment head leakage by 52% for 6 and 65% for 10 MV. Thus, peripheral doses were in general smaller for treatment plans calculated with unflattened beams. At about 20 cm distance from the field edge the dose was on average reduced by 23 and 31% for the 6 and 10 MV SBRT plans. For the IMRT plans (10 MV) the average reduction was 16% for the prostate and 18% for the head&neck case, respectively. For all examined cases, the relative deviation between peripheral doses of flattened and unflattened beams was found to increase with increasing distance from the field.

Conclusions

Removing the flattening filter lead to reduced peripheral doses for advanced treatment techniques. The relative difference between peripheral doses of flattened and unflattened beams was more pronounced when the nominal beam energy was increased. Patients may benefit by decreased exposure of normal tissue to scattered dose outside the field.     

Optimisation and evaluation of the foetal dose during a radiotherapy of the right parotid.]

Purpose was to optimize and to estimate the dose delivered to the foetus during a postoperative irradiation of a 5-month twin pregnant woman presenting with adenocarcinoma of the right parotid. The treatment protocol aimed to deliver 66Gy conformal radiation therapy on the tumour bed associated to a prophylactic irradiation of 50Gy on the upper cervical nodes. A series of measurements allowed to estimate the delivered dose in the abdomen by the means of an ion chamber inserted in a water phantom placed side by side of an anthropomorphic Alderson Rando phantom simulating the body of the patient from the head to the pelvis. An appropriate optimisation of the number and orientation of beams were performed in order to minimize the peripheral dose, which is mostly dependent of the total number of monitor unit per fraction: cervical nodes and tumour site included in the same fields, limitation of the irradiated volume, 6MV X-ray beams rather than Cobalt beams. The measured doses at the upper, in the middle and at the lower part of the abdomen were 17.0, 11.0 and 11.9mGy, respectively, for the entire treatment, representing 0.025, 0.016 and 0.017%, respectively of the prescribed dose. The actions conducted to optimise the treatment allowed to lower doses delivered to the foetus under the limits proposed by international recommendations (100mGy). Thus, the treatment of the pregnant patient had been performed with a minimized risk for the foetus.     

Patient dose from megavoltage computed tomography imaging

PURPOSE: Megavoltage computed tomography (MVCT) can be used daily for imaging with a helical tomotherapy unit for patient alignment before treatment delivery. The purpose of this investigation was to show that the MVCT dose can be computed in phantoms, and further, that the dose can be reported for actual patients from MVCT on a helical tomotherapy unit. METHODS AND MATERIALS: An MVCT beam model was commissioned and verified through a series of absorbed dose measurements in phantoms. This model was then used to retrospectively calculate the imaging doses to the patients. The MVCT dose was computed for five clinical cases: prostate, breast, head/neck, lung, and craniospinal axis. RESULTS: Validation measurements in phantoms verified that the computed dose can be reported to within 5% of the measured dose delivered at the helical tomotherapy unit. The imaging dose scaled inversely with changes to the CT pitch. Relative to a normal pitch of 2.0, the organ dose can be scaled by 0.67 and 2.0 for scans done with a pitch of 3.0 and 1.0, respectively. Typical doses were in the range of 1.0-2.0 cGy, if imaged with a normal pitch. The maximal organ dose calculated was 3.6 cGy in the neck region of the craniospinal patient, if imaged with a pitch of 1.0. CONCLUSION: Calculation of the MVCT dose has shown that the typical imaging dose is approximately 1.5 cGy per image. The uniform MVCT dose delivered using helical tomotherapy is greatest when the anatomic thickness is the smallest and the pitch is set to the lowest value.     

Dose verification in clinical IMRT prostate incidents

PURPOSE: In view of the need for dose-validation procedures on each individual intensity-modulated radiation therapy (IMRT) plan, dose-verification measurements by film, by ionization chamber, and by polymer gel-MRI dosimetry were performed for a prostate-treatment plan configuration. Treatment planning system (TPS) calculations were evaluated against dose measurements. METHODS AND MATERIALS: Intensity-modulated radiation therapy (IMRT) treatments were planned on a commercial TPS. Kodak EDR-2 films were used for the verification of two-dimensional (2D) dose distributions at 1 coronal and 5 axial planes in a water-equivalent phantom. Full three-dimensional (3D) dose distributions were measured by use of a novel polymer gel formulation and a 3D magnetic resonance imaging (MRI) readout technique. Calculations were compared against measurements by means of isocontour maps, gamma-index maps (3% dose difference, 3-mm distance to agreement) and dose-volume histograms. RESULTS: A good agreement was found between film measurements and TPS predictions for points within the 60% isocontour, for all the examined plans (gamma-index <1 for 96% of pixels). Three-dimensional dose distributions obtained with the polymer gel-MRI method were adequately matched with corresponding TPS calculations, for measurements in a gel phantom covering the planning-target volume (PTV). CONCLUSIONS: Measured 2D and 3D dose distributions suggest that, for the investigated prostate IMRT plan configuration, TPS calculations provide clinically acceptable accuracy.     

A multi-institutional initiative on patient-related quality assurance: Independent computational dose verification of fluence-modulated treatment techniques

PurposeThis multi-institutional study investigates whether computational verification of fluence-modulated treatment plans using independent software with its own Strahlerkopfmodel is an appropriate method for patient-related quality assurance (PRQA) in the context of various combinations of linear accelerators (linacs), treatment techniques and treatment planning systems (TPS).Materials and methodsThe PRQA-software's (Mobius3D) recalculations of 9 institutions’ treatment plans were analyzed for a horseshoe-shaped planning target volume (PTV) inside a phantom. The recomputed dose distributions were compared to a) the dose distributions as calculated by all TPS's and b) the measured dose distributions, which were acquired using the same independent measuring system for all institutions. Furthermore, dose volume histograms were examined. The penumbra deviations and mean gamma values were quantified using Verisoft (PTW). Additionally, workflow requirements for computational verification were discussed.ResultsMobius3D is compatible with all examined TPSs, treatment techniques and linacs. The mean PTV dose differences (Mobius3D-TPS, <3.0%) and 3D gamma passing rates (>95.0%) led to a positive plan acceptance result in all cases. These results are similar to the outcome of the dosimetric measurements with one exception. The mean gamma values (<0.5) show a good agreement between Mobius3D and the TPS dose distributions.ConclusionUsing Mobius3D was proven to be an appropriate computational PRQA method for the tested combinations of linacs, treatment techniques and TPS's. The clinical use of Mobius3D has to be complemented with regular dosimetric measurements and thorough linac and TPS QA. Mobius3D's computational verification reduced measurement effort and personnel needs in comparison to dosimetric verifications.     

Target and peripheral dose from radiation sector motions accompanying couch repositioning of patient coordinates with the Gamma Knife(®) Perfexion(™)

Background

The GammaPlan^™ treatment planning system (TPS) does not fully account for shutter dose when multiple shots are required to deliver a patient’s treatment. The unaccounted exposures to the target site and its periphery are measured in this study. The collected data are compared to a similar effect from the Gamma Knife^® model 4C.

Materials and methods.

A stereotactic head frame was attached to a Leksell^® 16 cm diameter spherical phantom; using a fiducial-box, CT images of the phantom were acquired and registered in the TPS. Measurements give the relationship of measured dose to the number of repositions with the patient positioning system (PPS) and to the collimator size. An absorbed dose of 10 Gy to the 50% isodose line was prescribed to the target site and all measurements were acquired with an ionization chamber.

Results

Measured dose increases with frequency of repositioning and with collimator size. As the radiation sectors transition between the beam on and beam off states, the target receives more shutter dose than the periphery. Shutter doses of 3.53±0.04 and 1.59±0.04 cGy/reposition to the target site are observed for the 16 and 8 mm collimators, respectively. The target periphery receives additional dose that varies depending on its position relative to the target.

Conclusions

The radiation sector motions for the Gamma Knife^® Perfexion^™ result in an additional dose due to the shutter effect. The magnitude of this exposure is comparable to that measured for the model 4C.     

Accuracy of out-of-field dose calculation of tomotherapy and cyberknife treatment planning systems: A dosimetric study

PurposeLate toxicities such as second cancer induction become more important as treatment outcome improves. Often the dose distribution calculated with a commercial treatment planning system (TPS) is used to estimate radiation carcinogenesis for the radiotherapy patient. However, for locations beyond the treatment field borders, the accuracy is not well known. The aim of this study was to perform detailed out-of-field-measurements for a typical radiotherapy treatment plan administered with a Cyberknife and a Tomotherapy machine and to compare the measurements to the predictions of the TPS.Materials and methodsIndividually calibrated thermoluminescent dosimeters were used to measure absorbed dose in an anthropomorphic phantom at 184 locations. The measured dose distributions from 6 MV intensity-modulated treatment beams for CyberKnife and TomoTherapy machines were compared to the dose calculations from the TPS.ResultsThe TPS are underestimating the dose far away from the target volume. Quantitatively the Cyberknife underestimates the dose at 40 cm from the PTV border by a factor of 60, the Tomotherapy TPS by a factor of two. If a 50% dose uncertainty is accepted, the Cyberknife TPS can predict doses down to approximately 10 mGy/treatment Gy, the Tomotherapy-TPS down to 0.75 mGy/treatment Gy. The Cyberknife TPS can then be used up to 10 cm from the PTV border the Tomotherapy up to 35 cm.ConclusionsWe determined that the Cyberknife and Tomotherapy TPS underestimate substantially the doses far away from the treated volume. It is recommended not to use out-of-field doses from the Cyberknife TPS for applications like modeling of second cancer induction. The Tomotherapy TPS can be used up to 35 cm from the PTV border (for a 390 cm³ large PTV).     

Dosimetric features of linac head and phantom scattered radiation outside the clinical photon beam: experimental measurements and comparison with treatment planning system calculations.

BACKGROUND AND PURPOSE: Dosimetric measurements and treatment planning system (TPS) calculations in the region outside the clinical photon beams have been investigated. The aim was to estimate the calculation accuracy of a specific TPS in areas that are becoming increasingly relevant with the advent of new technologies, such as, for example, intensity modulation radiation therapy. MATERIALS AND METHODS: Measurements were performed on two different linacs to obtain, separately, the head scatter (electrons and photons), the transmission below the jaws and the phantom scatter outside the primary beam for different photon energies, distances from the field edge and field sizes. Calculations with a commercial TPS (Helax TMS) were then obtained and compared with these measurements. RESULTS: In general, reasonable agreement between calculations and measurements was obtained (1-2%), especially for photon scattering (head and phantom). Nevertheless, some discrepancies were found in the electron contamination computation, due probably to the approximations and assumptions made in the TPS calculation algorithm. CONCLUSIONS: The analyzed TPS presented good results, but for some particular clinical cases and moreover for advanced techniques such as intensity modulated radiation therapy, the calculation behaviour with respect to measurements and patient dose delivery should be carefully evaluated.     

Radiation exposure during head repositioning with the automatic positioning system for gamma knife radiosurgery

PURPOSE: To measure radiation exposure to a patient during head repositioning with the automatic positioning system (APS) for Gamma Knife radiosurgery. METHODS AND MATERIALS: A 16-cm diameter spherical solid phantom, provided by the manufacturer, was mounted to the APS unit using a custom-made holder. A small-volume ionization chamber (0.07-cm(3) volume) was placed at the center of the phantom. We recorded the temporal variation of ionization current during the entire treatment. Measurements were made for 3 test cases and 7 clinical cases. RESULTS: The average transit time between successive shots, during which the APS unit was moving the phantom for repositioning the shot coordinates, was 20.5 s for 9 cases. The average dose rate, which was measured at the center of the phantom and at a point outside the shot location, was 0.36 +/- 0.09 cGy/min when the beam output was approximately 3.03 Gy/min for the 18-mm collimator helmet. Hence, the additional intracranial radiation dose during the APS-driven head repositioning between two successive shots (or APS transit dose) was 0.12 +/- 0.050 cGy. The APS transit dose was independent of the helmet size and the position of shots within the phantom relative to the measurement point. CONCLUSION: The head repositioning with the APS system adds a small but not negligible dose to the dose expected for the manual repositioning method.     

Assessing the difference between planned and delivered intensity-modulated radiotherapy dose distributions based on radiobiological measures

AimsBecause of the highly conformal distributions that can be obtained with intensity-modulated radiotherapy (IMRT), any discrepancy between the intended and delivered distributions would probably affect the clinical outcome. Consequently, there is a need for a measure that would quantify those differences in terms of a change in the expected clinical outcome.Materials and methodsTo evaluate such a measure, cancer of the cervix was used, where the bladder and rectum are proximal and partially overlapping with the internal target volume. A solid phantom simulating the pelvic anatomy was fabricated and a treatment plan was developed to deliver the prescribed dose to the phantom. The phantom was then irradiated with films positioned in several transverse planes. The racetrack microtron at 50 MV was used in the treatment planning and delivery processes. The dose distribution delivered was analysed based on the film measurements and compared against the treatment plan. The differences in the measurements were evaluated using both physical and biological criteria. Whereas the physical comparison of dose distributions can assess the geometric accuracy of delivery, it does not reflect the clinical effect of any measured dose discrepancies.ResultsIt is shown how small inaccuracies in delivered dose can affect the treatment outcome in terms of complication-free tumour cure.ConclusionsWith highly conformal IMRT, the accuracy of the patient set-up and treatment delivery are critical for the success of the treatment. A method is proposed to evaluate the precision of the delivered plan based on changes in complication and control rates as they relate to uncertainties in dose delivery.     

A comparison of optic nerve dosimetry in craniospinal radiotherapy planned and treated with conventional and intensity modulated techniques

Background and purpose

Some CNS tumours present leptomeningeal dissemination. Craniospinal radiotherapy is complex and recurrences may occur at sites of target volume underdosage. IMRT, being highly conformal to the target, could theoretically underdose the optic nerves if they are not specifically targeted leading to optic nerve recurrences. We analyzed optic nerve dosimetry when they are not specifically targeted.

Materials and methods

We designed 3D-conformal and tomotherapy plans for our last five patients treated to the craniospinal axis, not including the optic nerves in the target volume. We analyzed the dose delivered to the optic nerves, to the anterior and posterior half of the optic nerves, and to a theoretical optic nerve-PTV.

Results

The dose delivered to the optic nerves was similar for both plans in all patients (V95% close to 100%) except one in whom tomotherapy considerably underdosed the anterior optic nerves. The dose to the optic nerve-PTV was lower with tomotherapy in all patients.

Conclusion

Despite not intentionally targeting the optic nerves, the dose to the optic nerves with IMRT was similar to 3D-conformal plans in most cases but left no margin for setup error. In individual cases the anterior half of the optic nerves could be significantly underdosed.     

Thyroid dose in children undergoing prophylactic cranial irradiation

Purpose: To determine the radiation dose received by the thyroid gland as a result of prophylactic cranial irradiation (PCI) in childhood leukemia and the factors influencing that dose.Methods and Materials: The dose to the thyroid resulting from simulated cranial irradiation with parallel opposed lateral fields of an adult anthropomorphic (ART) phantom with both 6 MV X-rays and Cobalt-60 γ-rays was measured using thermoluminescent dosimeters (TLDs). The dependence of thyroid dose on the distance of the field from the thyroid and the proportions of thyroid dose from stray radiation (leakage, scatter from jaws, etc.) and tissue scattered radiation were measured. The effects of a shadow tray and shielding blocks were also determined. Calculation of thyroid dose using the Clarkson scatter integration method was performed for 6 MV X-rays to compare with the measured doses. In vivo thyroid dose estimates were made using TLD measurements for three children receiving PCI with 6 MV X-rays.Results: Using open, unshielded fields, the thyroid region of the phantom received 1.2–1.4% of the prescribed cranial dose for 6 MV X-rays and 1.5–1.7% for Cobalt-60. For both treatment units, stray radiation accounted for approximately two thirds of the thyroid dose and tissue scatter accounted for the remaining one third. The thyroid dose increased as the field moved closer to the thyroid, with an increasing proportion of the dose due to tissue scatter. Placement of a thyroid shielding block on a shadow tray reduced the thyroid dose by only 20% compared with the open, unshielded setup. Thyroid dose from 6 MV using open fields was affected by the orientation of the collimator. When the inferior field edge was defined by the lower jaw, the dose was reduced by 27% compared with the upper jaw. Good correlation of dose to the thyroid region was obtained between phantom measured doses, in vivo measured doses and calculation of dose using the Clarkson method.Conclusion: For PCI doses of 1800 or 2400 cGy in the adult phantom, the dose to the thyroid was 20–40 cGy (1–2%). For small children this could rise to approximately 5% of the prescribed dose, of which half was due to stray radiation. As the thyroid in children is very sensitive to radiation and the dose-response curve for thyroid tumor induction is linear, attempts to shield the thyroid during cranial irradiation are mandatory. Cobalt-60 units should not be used, as the thyroid dose was higher than using 6 MV X-rays. Collimator orientation and the use of shadow trays and shielding were important factors in determining thyroid dose.     

Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy

PURPOSE: For intensity-modulated radiotherapy of nasopharyngeal cancer, accurate dose delivery is crucial to the success of treatment. This study aimed to evaluate the significance of daily image-guided patient setup corrections and to quantify the parotid gland volume and dose variations for nasopharyngeal cancer patients using helical tomotherapy megavoltage computed tomography (CT). METHODS AND MATERIALS: Five nasopharyngeal cancer patients who underwent helical tomotherapy were selected retrospectively. Each patient had received 70 Gy in 35 fractions. Daily megavoltage CT scans were registered with the planning CT images to correct the patient setup errors. Contours of the spinal cord and parotid glands were drawn on the megavoltage CT images at fixed treatment intervals. The actual doses delivered to the critical structures were calculated using the helical tomotherapy Planned Adaptive application. RESULTS: The maximal dose to the spinal cord showed a significant increase and greater variation without daily setup corrections. The significant decrease in the parotid gland volume led to a greater median dose in the later phase of treatment. The average parotid gland volume had decreased from 20.5 to 13.2 cm3 by the end of treatment. On average, the median dose to the parotid glands was 83 cGy and 145 cGy for the first and the last treatment fractions, respectively. CONCLUSIONS: Daily image-guided setup corrections can eliminate significant dose variations to critical structures. Constant monitoring of patient anatomic changes and selective replanning should be used during radiotherapy to avoid critical structure complications.     

Measured peripheral dose in pediatric radiation therapy: a comparison of intensity-modulated and conformal techniques.

BACKGROUND AND PURPOSE: The interest in IMRT for the treatment of pediatric malignancies has raised concern about possible increased total body dose. This study examines the pediatric peripheral dose resulting from IMRT compared to 3D conformal therapy. METHODS AND MATERIALS: Five brain or base of skull pediatric cases were planned with both IMRT and 3D conformal techniques. A pediatric-sized anthropomorphic phantom was created and ion chambers were placed at interest points approximating the position of the thyroid, breast, ovary and testes. Measured peripheral doses at the interest points were compared for both IMRT and 3D conformal techniques for the 5 cases. RESULTS: While tumor coverage was similar for both techniques, the IMRT delivery resulted in lower peripheral doses at points near the target (thyroid) presumably due to reduced internal scatter from a smaller effective field size for sliding window dynamic multi-leaf collimation. The IMRT delivery resulted in higher doses to the more distant points, presumably due to the higher monitor units and resulting increased head leakage. Since the magnitude of dose at the distant points was much smaller than that of the thyroid point, the overall absolute peripheral dose was similar for both techniques. CONCLUSIONS: Peripheral dose is difficult to predict by monitor units alone. In this study, interest points closer to the beam received less dose with IMRT. This difference may result from the competing factors of reduced internal scatter from dynamic multileaf collimation IMRT and reduced head leakage for 3D conformal therapy.